NCT03703427

Capecitabine Versus Vinorelbine in High Risk Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy

Randomised, Multicenter Phase II Study in Patients With High Risk Breast Cancer With Capecitabine Versus Vinorelbine With Pathologic Residual Tumors After Preoperative Chemotherapy Secondary ID

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 200 (estimated)
• Sponsor: Zhiyong Yu · Academic / Other
• Sex: Female
• Age: 20 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to investigate the efficacy and safety of capecitabine versus vinorelbine as a postoperative adjuvant chemotherapy, for high risk breast cancer patients who have pathologic residual cancer cells after the preoperative chemotherapy.

Conditions

• Pathologic Residual Cancer Cells

Interventions

Type	Name	Description
DRUG	Capecitabine, Oral, 500 Mg	1250mg/m2，d1-d14，q3w
DRUG	Vinorelbine Tartrate Oral	60mg/m2，d1；d8；q3w

Timeline

• Start date: 2018-11-01
• Primary completion: 2023-11-01
• Completion: 2025-11-01
• First posted: 2018-10-12
• Last updated: 2018-10-12

Locations

1 site across 1 country: China